U.S. Markets open in 6 hrs 18 mins
  • Gold

    1,779.60
    +13.90 (+0.79%)
     
  • EUR/USD

    1.1656
    +0.0038 (+0.3264%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • Vix

    16.31
    +0.01 (+0.06%)
     
  • GBP/USD

    1.3772
    +0.0045 (+0.3250%)
     
  • USD/JPY

    114.0260
    -0.2860 (-0.2502%)
     
  • BTC-USD

    62,179.16
    -182.26 (-0.29%)
     
  • CMC Crypto 200

    1,449.54
    -2.09 (-0.14%)
     
  • FTSE 100

    7,203.83
    0.00 (0.00%)
     
  • Nikkei 225

    29,215.52
    +190.06 (+0.65%)
     

Did You Miss Reata Pharmaceuticals' (NASDAQ:RETA) Whopping 681% Share Price Gain?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) shareholders might be concerned after seeing the share price drop 10% in the last month. But that does not change the realty that the stock's performance has been terrific, over five years. In that time, the share price has soared some 681% higher! So it might be that some shareholders are taking profits after good performance. The most important thing for savvy investors to consider is whether the underlying business can justify the share price gain. While the long term returns are impressive, we do have some sympathy for those who bought more recently, given the 15% drop, in the last year.

It really delights us to see such great share price performance for investors.

Check out our latest analysis for Reata Pharmaceuticals

Given that Reata Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Over the last half decade Reata Pharmaceuticals' revenue has actually been trending down at about 25% per year. This is in stark contrast to the strong share price growth of 51%, compound, per year. There can be no doubt this kind of decoupling of revenue growth and share price growth is unusual to see in loss making companies. At the risk of upsetting holders, this does suggest that hope for a better future is playing a significant role in the share price action.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

Investors in Reata Pharmaceuticals had a tough year, with a total loss of 15%, against a market gain of about 38%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 51% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for Reata Pharmaceuticals you should be aware of.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.